MedImmune said Tuesday it has inked a deal with two nonprofit cancer institutes that will advance three of the Gaithersburg biotech's antibodies through the clinic.
Under the deal, the Cancer Research Institute and the Ludwig Institute for Cancer Research, both based in New York, will conduct clinical trials of the early- and mid-stage therapeutics, each of which is designed to harness the body’s immune system to target tumors. The trials will involve combinations of different immunotherapies.